Subconjunctival administration of low-dose murine allogeneic mesenchymal stromal cells promotes corneal allograft survival in mice.
Allogeneic
Corneal transplantation
Graft survival
Immunomodulation
Macrophage
Mesenchymal stromal cells
Mouse
Subconjunctival
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
06 04 2021
06 04 2021
Historique:
received:
20
01
2021
accepted:
17
03
2021
entrez:
7
4
2021
pubmed:
8
4
2021
medline:
13
7
2021
Statut:
epublish
Résumé
Systemic administration of mesenchymal stromal cells (MSCs) has been efficacious in many inflammatory disease settings; however, little data are available on the potential immunomodulatory effects following local MSC administration in the context of corneal transplantation. The purpose of this study was to assess the potential of subconjunctival injection of MSCs to promote corneal allograft survival. MSCs were isolated from female C57BL/6 (H-2 Both high- and low-dose injection of allogeneic MSCs on day - 7 led to 100% graft survival over the observation period. Moreover, low-dose dual subconjunctival injection of 5 × 10 This work demonstrates that low-dose subconjunctival injection of allogeneic MSCs successfully promotes corneal allograft survival and may contribute to refining future MSC immunotherapies for prevention of corneal allograft rejection.
Sections du résumé
BACKGROUND
Systemic administration of mesenchymal stromal cells (MSCs) has been efficacious in many inflammatory disease settings; however, little data are available on the potential immunomodulatory effects following local MSC administration in the context of corneal transplantation. The purpose of this study was to assess the potential of subconjunctival injection of MSCs to promote corneal allograft survival.
METHODS
MSCs were isolated from female C57BL/6 (H-2
RESULTS
Both high- and low-dose injection of allogeneic MSCs on day - 7 led to 100% graft survival over the observation period. Moreover, low-dose dual subconjunctival injection of 5 × 10
CONCLUSION
This work demonstrates that low-dose subconjunctival injection of allogeneic MSCs successfully promotes corneal allograft survival and may contribute to refining future MSC immunotherapies for prevention of corneal allograft rejection.
Identifiants
pubmed: 33823917
doi: 10.1186/s13287-021-02293-x
pii: 10.1186/s13287-021-02293-x
pmc: PMC8025388
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
227Références
Mol Ther. 2020 Sep 2;28(9):2023-2043
pubmed: 32531237
JCI Insight. 2020 Jun 18;5(12):
pubmed: 32453713
Am J Transplant. 2014 Sep;14(9):2023-36
pubmed: 25307035
Ocul Surf. 2019 Oct;17(4):729-736
pubmed: 31279065
Mol Ther. 2012 Nov;20(11):2143-52
pubmed: 22929658
Stem Cells. 2012 Jul;30(7):1565-74
pubmed: 22522999
BMC Ophthalmol. 2018 Jun 8;18(1):139
pubmed: 29884142
F1000Res. 2020 Feb 27;9:
pubmed: 32148780
Transplantation. 2019 Dec;103(12):2468-2478
pubmed: 31765363
Am J Transplant. 2004 May;4(5):678-85
pubmed: 15084160
FASEB J. 2019 Aug;33(8):9404-9421
pubmed: 31108041
Eur J Immunol. 2011 Oct;41(10):2840-51
pubmed: 21710489
Curr Opin Organ Transplant. 2016 Dec;21(6):559-567
pubmed: 27801687
Invest Ophthalmol Vis Sci. 2014 Sep 16;55(10):6631-8
pubmed: 25228546
PLoS One. 2012;7(2):e30842
pubmed: 22363499
J Cell Mol Med. 2012 Sep;16(9):2094-103
pubmed: 22151542
Stem Cells. 2013 Oct;31(10):2033-41
pubmed: 23766124
Proc Natl Acad Sci U S A. 2016 Jan 5;113(1):158-63
pubmed: 26699483
Front Immunol. 2018 Nov 20;9:2666
pubmed: 30515159
Stem Cells. 2018 Aug;36(8):1210-1215
pubmed: 29726063
Acta Ophthalmol. 2009 Aug;87(5):488-97
pubmed: 19664109